Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Opinion|Videos|February 28, 2026
Matthew Galsky, MD, on infrastructure and education in BCG/ICI integration
Author(s)Matthew Galsky, MD
Fact checked by: Hannah Clarke, Tracy Ann Politowicz
Matthew D. Galsky, MD, discusses what is needed for successful integration of BCG/ICI combinations in BCG-naive non–muscle invasive bladder cancer.
Advertisement
In the following video, Matthew D. Galsky, MD, emphasizes that the successful integration of BCG/immune checkpoint inhibitor (ICI) combinations in BCG-naive non–muscle invasive bladder cancer (NMIBC) will depend on logistics, infrastructure, team education, and a coordinated recognition of immune-related adverse events across urology and oncology practices. Galsky is a professor of medicine at the Icahn School of Medicine at Mount Sinai and the director of GU medical oncology at the Tisch Cancer Center in New York, New York.
Advertisement
Related to this article
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
Advertisement
Advertisement
Trending on Urology Times
1
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
In situ immunotherapy shows encouraging survival findings in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5